[18F]F-FAPI PET/CT在预测狼疮性肾炎治疗反应方面优于[18F]F-FDG PET/CT
前瞻性纳入20例经活检证实的狼疮性肾炎患者,诱导治疗前接受[18F]F-FAPI与[18F]F-FDG双示踪剂PET/CT,6个月评估完全缓解(CR)、部分缓解(PR)和无反应(NR)。基线肾FAPI SUVmax与TBR在CR组显著低于非CR组,FAPI视觉评估预测CR的准确率85%、特异度90%、阳性预测值89%,均高于FDG;多因素分析中基线FAPI摄取阴性是CR的唯一独立预测因素。
要点
- 基线肾FAPI SUVmax与eGFR负相关、与ESR正相关(均P<0.05),FDG SUVmax与两者均无显著相关。
- 6个月时50%患者达CR、25%达PR、25%为NR;CR组基线肾FAPI SUVmax和TBR显著低于非CR组(P<0.01)。
- FAPI视觉评估预测CR的准确率85% vs FDG 70%,特异度90% vs 50%,PPV 89% vs 64%,敏感度和NPV相当。
核心结论
- [18F]F-FAPI PET/CT对狼疮性肾炎短期治疗反应的预测性能优于[18F]F-FDG PET/CT。
- 基线FAPI摄取阴性是多因素分析中CR的唯一独立预测因素(P<0.01)。
- 作者认为其有潜力作为无创影像生物标志物指导临床决策和优化个体化治疗。
研究设计与样本
- 前瞻性纳入20例经活检证实的狼疮性肾炎患者,诱导治疗前接受[18F]F-FAPI与[18F]F-FDG双示踪剂PET/CT成像。
- 6个月时评估治疗反应,分为完全缓解(CR)、部分缓解(PR)和无反应(NR)组。
- 分析PET指标(肾SUVmax、靶本比TBR)、临床生物标志物与治疗反应之间的关联。
主要发现
- 基线肾FAPI SUVmax与估计肾小球滤过率(eGFR)负相关、与红细胞沉降率(ESR)正相关(均P<0.05),FDG SUVmax与两者均无显著相关。
- 6个月时50%患者达CR、25%达PR、25%为NR。
- CR组基线肾FAPI SUVmax和TBR显著低于非CR组(PR+NR)(P<0.01)。
- FAPI视觉评估预测CR的准确率85% vs FDG 70%、特异度90% vs 50%、阳性预测值(PPV)89% vs 64%,敏感度和阴性预测值(NPV)相当。
- 单因素logistic回归显示年龄>35岁(P<0.05)和基线FAPI摄取阴性(P<0.01)为CR的显著预测因素;多因素分析中基线FAPI摄取阴性是唯一独立预测因素(P<0.01)。
关键数值与推荐
- FAPI视觉评估预测CR:准确率85%、特异度90%、PPV 89%;FDG对应为准确率70%、特异度50%、PPV 64%。
- 单因素logistic回归:年龄>35岁P<0.05,基线FAPI摄取阴性P<0.01。
- 多因素分析:基线FAPI摄取阴性P<0.01,为唯一独立预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify predictors of complete response (CR) following induction therapy in lupus nephritis (LN) and comparatively evaluate the predictive value of baseline [18 F]F-FAPI PET/CT versus [18 F]F-FDG PET/CT for treatment short-term outcomes. MATERIALS AND METHODS: Twenty biopsy-proven LN patients were prospectively enrolled and underwent dual-tracer PET/CT imaging, using both [18 F]F-FAPI and [18 F]F-FDG imaging prior to standardized induction therapy. Treatment response was assessed at 6 months, categorizing into CR, partial response (PR), and non-response (NR) groups. Associations between PET metrics, clinical biomarkers and treatment response were analyzed. Semiquantitative PET parameters including renal standardized uptake values (SUVmax) and target-to-background ratio (TBR) were calculated. RESULTS: Baseline renal FAPI SUVmax was inversely correlated with estimated glomerular filtration rate (eGFR) and positively with erythrocyte sedimentation rate (ESR) (P < 0.05 for both), whereas FDG SUVmax showed no significant correlation with either parameter. At 6 months, 50% of patients achieved CR, 25% PR, and 25% NR. Patients with CR exhibited significantly lower baseline renal FAPI SUVmax and TBR compared to those with non-CR (PR + NR) (P < 0.01). Visual assessment of FAPI uptake outperformed FDG in predicting CR, with higher accuracy (85% vs. 70%), specificity (90% vs. 50%), and positive predictive value (PPV, 89% vs. 64%), while sensitivity and negative predictive value (NPV) were comparable. Univariate logistic regression identified age > 35 years (P < 0.05) and negative baseline FAPI uptake (P < 0.01) as significant predictors of CR. In multivariate analysis, negative FAPI uptake remained the only independent predictor (P < 0.01). CONCLUSION: [18 F]F-FAPI PET/CT demonstrates superior predictive performance over [18 F]F-FDG PET/CT for short-term treatment response in lupus nephritis. It holds promise as a noninvasive imaging biomarker to guide clinical decision-making and optimize individualized therapy.
引用
- Zhao M, Zhou C, Fang H, et al. [18F]F-FAPI PET/CT outperforms [18F]F-FDG PET/CT in predicting treatment response in lupus nephritis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40830669. doi:10.1007/s00259-025-07523-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。